[1]
S. I. SETIAWAN and P. ASCOBAT, “ADVERSE REACTIONS TO FIRST-LINE ANTI-TUBERCULOSIS DRUGS AS A RISK FACTOR OF PULMONARY TUBERCULOSIS TREATMENT DEFAULT IN JAKARTA, INDONESIA”, Int J App Pharm, vol. 11, no. 6, pp. 80–83, Dec. 2019.